v3.25.4
Summary of significant accounting policies - Narrative (Details)
$ / shares in Units, $ in Millions
 12 Months Ended
Aug. 23, 2023
May 08, 2023
USD ($)
$ / shares
shares
Dec. 28, 2025
USD ($)
Segment
Employee
$ / shares
Dec. 29, 2024
USD ($)
$ / shares
Dec. 31, 2023
USD ($)
Jan. 02, 2022
Jan. 03, 2021
Jul. 02, 2023
USD ($)
Concentration of Credit Risk [Line Items]                
Number of employees | Employee     138,200          
Common Stock, Par or Stated Value Per Share | $ / shares     $ 1.00 $ 1.00        
Proceeds from Kenvue initial public offering     $ 0 $ 0 $ 4,241      
Realized gain (loss) on investment   $ 2,500            
Number of business segments | Segment     2          
Supplier finance program, obligation, current     $ 784 $ 788 $ 704      
Supplier Finance Program, Obligation, Current, Statement of Financial Position [Extensible Enumeration]     Accounts Payable, Current Accounts Payable, Current        
Minimum reverse repurchase agreement collateral (as a percent)     102.00%          
Accrued rebates, returns and promotions     $ 19,124 $ 17,580        
Sales return reserve (as a percent)     1.00% 1.00% 1.00%      
Percentage of profit share payments (less than)     2.00% 2.00%        
Cost of products sold     $ 30,256 $ 27,471 $ 26,553      
Shipping and handling costs as a percent of sales     1.00% 1.00% 1.00%      
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]     Other assets, noncurrent Other assets, noncurrent        
Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]     Accrued Liabilities, Current, Other Liabilities, Noncurrent Accrued Liabilities, Current, Other Liabilities, Noncurrent        
Operating lease, right-of-use asset     $ 1,300 $ 1,100        
Operating lease liabilities     1,400 1,200        
Operating lease costs     200 200 $ 200      
Cash paid for operating leases     300 200 200      
Advertising expense     $ 1,600 $ 600 $ 500      
U.S. statutory rate     21.00% 21.00% 21.00% 21.00% 35.00%  
TCJA, undistributed foreign earnings percent related to cash and cash equivalents           15.50%    
TCJA, undistributed foreign earnings percent related to earnings other than cash and cash equivalents           8.00%    
TCJA, transition tax for accumulated foreign earnings, payment period     8 years          
TJCA , provisional liability, non-current     $ 2,500          
Repatriation of foreign earnings amount     600          
Selling, marketing and administrative expenses     $ 23,676 $ 22,869 $ 21,512      
Supplier finance program, payment timing, period     90 days          
Yellow Jersey Therapeutics                
Concentration of Credit Risk [Line Items]                
Payments to Acquire in Process Research and Development     $ 1,250 $ 1,250        
Kenvue Inc.                
Concentration of Credit Risk [Line Items]                
Split-off percentage 80.10%              
Kenvue Inc.                
Concentration of Credit Risk [Line Items]                
Common Stock, Par or Stated Value Per Share | $ / shares   $ 0.01            
Sale of stock (in USD per share) | $ / shares   $ 22.00            
Johnson & Johnson | Kenvue Inc.                
Concentration of Credit Risk [Line Items]                
Percentage ownership after transaction   89.60%            
Common stock, value               $ 1,300
Percentage ownership after transaction 9.50%              
IPO | Kenvue Inc.                
Concentration of Credit Risk [Line Items]                
Sale of stock, number of shares issued in transaction (in shares) | shares   198,734,444            
Proceeds from Kenvue initial public offering   $ 4,200            
Minimum                
Concentration of Credit Risk [Line Items]                
Revenue, performance obligation, payment terms     30 days          
Adjustment to revenue recognized     3.00%          
Minimum | Software Development                
Concentration of Credit Risk [Line Items]                
Estimated useful lives of the assets     5 years          
Maximum                
Concentration of Credit Risk [Line Items]                
Revenue, performance obligation, payment terms     90 days          
Adjustment to revenue recognized     2.00%          
Maximum | Software Development                
Concentration of Credit Risk [Line Items]                
Estimated useful lives of the assets     8 years          
R&D Expense | Project Concentration Risk                
Concentration of Credit Risk [Line Items]                
Concentration risk, threshold percentage (as a percent)     0.05 0.05 0.05      
Shipping and Handling                
Concentration of Credit Risk [Line Items]                
Selling, marketing and administrative expenses     $ 900 $ 900 $ 900      
Pharmaceutical                
Concentration of Credit Risk [Line Items]                
Accrued rebates, returns and promotions     $ 13,000 $ 12,300